Search results for "recurrence"

showing 10 items of 1036 documents

Role of robotic surgery in ovarian malignancy

2017

As part of minimally invasive surgery, robotic-assisted approach is becoming increasingly popular in gynecologic oncology. It has been shown to be effective and feasible for staging and treating endometrial and cervical cancer, but its role in the context of primary and recurrent ovarian cancers is presently debated. Scanty data are available in the literature, and the level of evidence supporting its use in ovarian cancer is quite low. However, from a retrospective case-control series, robotic surgery seems to be safe and feasible for early-stage ovarian cancer. Its use in treating patients with advanced-stage or relapsed ovarian cancer is still highly controversial, suggesting the choice …

Oncologymedicine.medical_specialtyPopulationContext (language use)robotic surgery ovarian cancerGynecologic oncologygynecologic oncology03 medical and health sciencesGynecologic Surgical Procedures0302 clinical medicineRobotic Surgical ProceduresInternal medicinerobotic surgerymedicineHumansRobotic surgeryeducationOvarian malignancygynecologic oncology; minimally invasive surgery; ovarian cancer; robotic surgery; Obstetrics and Gynecologyminimally invasive surgeryNeoplasm StagingRetrospective StudiesOvarian NeoplasmsCervical cancereducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryGeneral surgeryObstetrics and GynecologyGeneral MedicineEvidence-based medicinemedicine.diseasegynecologic oncology; minimally invasive surgery; ovarian cancer; robotic surgery; Case-Control Studies; Female; Gynecologic Surgical Procedures; Humans; Neoplasm Recurrence Local; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Robotic Surgical Procedures; Treatment OutcomeTreatment Outcomeovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIACase-Control Studies030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessOvarian cancer
researchProduct

Tumor Size, an Additional Risk Factor of Local Recurrence in Low-Risk Endometrial Cancer: A Large Multicentric Retrospective Study.

2018

ObjectiveThe identification of patients with endometrial cancer (EC) at higher risk for relapse is critical to individualize and better tailor postoperative treatment. No evidence is available regarding the possible association between tumor size (TS) and the risk of local recurrence. The purpose of this study was to analyze the correlation between TS and risk/type of recurrence in EC patients, stratified according to the new European Society of Medical Oncology-European Society of Gynecological Oncology-European Society for Radiotherapy and Oncology classification.MethodsData of patients with histologically proven EC who received primary surgical treatment between November 1999 and June 20…

Oncologymedicine.medical_specialtyPrognostic factormedicine.medical_treatmentRome03 medical and health sciencesEndometrium0302 clinical medicineEndometrial cancerRetrospective StudieRisk FactorsInternal medicinemedicineLocal recurrenceHumansEndometrial NeoplasmRisk factorAgedRetrospective Studies030219 obstetrics & reproductive medicineReceiver operating characteristicTumor sizebusiness.industryRisk FactorEndometrial cancerDistant relapseLocal relapseObstetrics and GynecologyRetrospective cohort studyTumor sizeMiddle Agedmedicine.diseaseEndometrial NeoplasmsRadiation therapyEndometrial cancer; Local recurrence; Local relapse; Tumor size; Vaginal relapse; Oncology; Obstetrics and GynecologyNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIALocalReproductive MedicineOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessVaginal relapseHumanInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Progress of Phototherapy Applications in the Treatment of Bone Cancer

2021

Bone cancer including primary bone cancer and metastatic bone cancer, remains a challenge claiming millions of lives and affecting the life quality of survivors. Conventional treatments of bone cancer include wide surgical resection, radiotherapy, and chemotherapy. However, some bone cancer cells may remain or recur in the local area after resection, some are highly resistant to chemotherapy, and some are insensitive to radiotherapy. Phototherapy (PT) including photodynamic therapy (PDT) and photothermal therapy (PTT), is a clinically approved, minimally invasive, and highly selective treatment, and has been widely reported for cancer therapy. Under the irradiation of light of a specific wa…

Oncologymedicine.medical_specialtyQH301-705.5Photothermal Therapymedicine.medical_treatmentCancer therapyBone NeoplasmsPhotodynamic therapyReviewCatalysisInorganic ChemistryInternal medicineHumansMedicineBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopyOsteosarcomaChemotherapyPhotosensitizing Agentsbusiness.industryBone cancerOrganic ChemistryCancerbone cancerGeneral MedicinePhototherapyPhotothermal therapymedicine.diseaseComputer Science ApplicationsRadiation therapyChemistryPrimary bonephotodynamic therapyPhotochemotherapyNanoparticlesGoldtumor therapyNeoplasm Recurrence LocalReactive Oxygen SpeciesbusinessInternational Journal of Molecular Sciences
researchProduct

Cetuximab in squamous cell head and neck carcinomas.

2007

The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been shown to enhance the effects of radiotherapy, and reports to date indicate that this effect occurs without any change in the pattern and severity of toxicity usually associated with head and neck radiation and/or chemotherapy (CT) administration. Moreover, several studies have reported that the expression of EGFR is strongly linked to poor outcome in patients undergoing therapy. Therefore, the presence of the EGFR in almost all cases of head and neck carcinoma offers a new therapeutic opportunity to most patients. In this paper, we report a review of the major studies dealing with the use of cetuximab in ad…

Oncologymedicine.medical_specialtyRadiation-Sensitizing Agentsmedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineCarcinomaAnimalsHumansEpidermal growth factor receptorSquamous epithelial cellCetuximabbiologyClinical Trials Phase I as Topicbusiness.industryHead and neck cancerAntibodies MonoclonalHematologymedicine.diseaseHead and neck squamous-cell carcinomaChemotherapy regimenRadiation therapyneck carcinomasmedicine.anatomical_structureOncologyHead and Neck Neoplasmsbiology.proteinCarcinoma Squamous CellNeoplasm Recurrence Localbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Tumor biology in older breast cancer patients – What is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohor…

2015

Abstract Purpose The tumor biology of older breast cancer patients (oBCP) is usually less aggressive, however applied adjuvant treatment is often less potent resulting in an impaired disease free survival and overall survival in this group. This study tries to answer the following questions for the biological subtypes of oBCP (70+ y): (1) Is there a significant difference in the distribution of the biological subtypes of oBCP vs younger breast cancer patients (yBCP; 50–69 y)? (2) Which biological subtype has the highest rate of non-guideline-adherent-treatment (GL−) among oBCP? (3) Is a single GL− (i.e. radiotherapy/surgery/endocrine-therapy/chemotherapy) significantly associated with the s…

Oncologymedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentBreast NeoplasmsBreast cancerGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedRetrospective StudiesChemotherapybusiness.industryTumor biologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseSurvival AnalysisRadiation therapyTreatment OutcomeChemotherapy AdjuvantHormone receptorFemaleSurgeryGuideline AdherenceHealth Impact AssessmentNeoplasm Recurrence LocalbusinessAdjuvantCohort studyThe Breast
researchProduct

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

2021

Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients ( n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA ( n = 2343, 12.1%) were older, more disa…

Oncologymedicine.medical_specialtyRelapsing-RemittingMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineDisease registryRecurrenceRisk Factorsbig dataInternal medicinemedicineHumansdata-driven algorithmMultiple sclerosi030212 general & internal medicinebig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressive; Disease Progression; Humans; Recurrence; Risk Factors; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-RemittingSecondary progressiveTransition (genetics)business.industryMultiple sclerosisMultiple Sclerosis Chronic Progressivemedicine.diseaseChronic ProgressiveNeurologybig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressiveDisease Progressiondisease registrysecondary progressiveSettore MED/26 - NeurologiaNeurology (clinical)prognosisbusinessprognosi030217 neurology & neurosurgery
researchProduct

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

2019

Oncologymedicine.medical_specialtySalvage therapyDrug resistanceLymphoma Mantle-Cellchemistry.chemical_compoundText miningPiperidinesInternal medicinemedicineHumansOnline Only ArticlesSurvival rateSalvage TherapyClinical Trials as Topicbusiness.industryAdenineHematologymedicine.diseasePrognosisLymphomaSurvival RatePyrimidineschemistryDrug Resistance NeoplasmIbrutinibRelapsed refractoryPyrazolesMantle cell lymphomaNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

2014

Introduction: Treatment of ovarian cancer has been long standardized with the inclusion of surgery and chemotherapy based on platinum and taxanes, this strategy reaching high remission rates. However, when this treatment fails, further options are available with little benefit. Since ovarian cancer has specific immunologic features, actually immunotherapy is under evalua- 15 tion to overcome treatment failure in patients experiencing recurrence. Areas covered: Immunogenicity of ovarian cancer and its relationship with clinical outcomes is briefly reviewed. The kinds of immunotherapeutic strategies are summarized. The clinical trials investigating immunotherapy in recurrent ovarian cancer pa…

Oncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryTreatment failureInternal medicineDrug DiscoverymedicineAnimalsHumansIn patientTreatment FailureBiologyOvarian Neoplasmsantibody cancer vaccines cell transfer immune system immunotherapy ovarian cancer recurrence treatment strategiesPharmacologyChemotherapybusiness.industryTreatment optionsImmunotherapymedicine.diseaseClinical trialRecurrent Ovarian CancerImmunologyFemaleImmunotherapyHuman medicineNeoplasm Recurrence LocalOvarian cancerbusinessEngineering sciences. TechnologyExpert Opinion on Biological Therapy
researchProduct

Factors accelerating recurrences and secondary tumors in cutaneous squamous cell carcinoma

2020

To investigate factors that affect and also decrease the duration for recurrences and secondary tumors in cSCC. A retrospective study was conducted for all patients who were treated for a cSCC of the head and neck between 2009 and 2016. Anamnestic as well as epidemiological and histological data were noted and correlated with the occurrence of recurrences and secondary cancers. The duration between surgery and these events was used to determine if histological factors accelerate their occurrence. The highest risk for recurrences was seen in patients with previous skin cancers (RR 3.23). Histological ulceration (p = 0.003) and grading (p = 0.031) of the tumor were found as significant factor…

Oncologymedicine.medical_specialtySkin NeoplasmsCutaneous squamous cell carcinoma03 medical and health sciences0302 clinical medicineRisk FactorsSurgical oncologyInternal medicineEpidemiologymedicineTumor GradingHumansStage (cooking)Grading (tumors)Retrospective Studiesbusiness.industryRetrospective cohort study030206 dentistryOtorhinolaryngologyHead and Neck Neoplasms030220 oncology & carcinogenesisCarcinoma Squamous CellSurgerySecondary tumorsNeoplasm Recurrence LocalOral SurgerybusinessJournal of Cranio-Maxillofacial Surgery
researchProduct

Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA).

1993

Oncologymedicine.medical_specialtybusiness.industryGeneral NeuroscienceEndocrine therapyBreast Neoplasmsmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyPostmenopauseTamoxifenBreast cancerHistory and Philosophy of SciencePremenopauseReceptors EstrogenChemotherapy AdjuvantRecurrenceInternal medicinemedicineCooperative groupHumansFemalebusinessEarly breast cancerProbability
researchProduct